ADM: A Promising Potential Drug Target and Biomarker (G133)

Target Name: ADM

NCBI ID: G133

Content of Review Report on ADM Target / Biomarker

ADM

ADM: A Promising Potential Drug Target and Biomarker

ADM (proadrenomedullin N-20 terminal peptide) is a 20-amino acid terminal peptide that is synthesized in the adrenal glands, and is known for its ability to stimulate the production of adrenocorticotropic hormone (ACTH) in the pituitary gland. ADM has been shown to have a variety of physiological effects, including the regulation of inflammation, stress responses, and sexual function.

One of the most promising aspects of ADM is its potential as a drug target. The ADM peptide has been shown to interact with various signaling pathways, including the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and inflammation, and is a key player in the development of cancer.

ADM has also been shown to interact with the NF-kappa-B pathway, a signaling pathway that is involved in the regulation of inflammation and immune responses. This suggests that ADM may have potential as a therapeutic agent for the treatment of a variety of inflammatory and autoimmune diseases.

In addition to its potential as a drug target, ADM also has the potential as a biomarker. The ADM peptide has been shown to have a variety of potential biomarker properties, including its ability to serve as a protein biomarker for the diagnosis of cancer, as well as its ability to serve as a target for diagnostic tests for a variety of diseases.

The ADM peptide is also a good candidate for a diagnostic marker for cancer, as it has been shown to have a positive correlation with the expression of proadrenocorticotropic hormone (ACTH), which is a hormone produced by the adrenal glands that is involved in the regulation of many physiological processes, including the regulation of inflammation and stress responses.

In addition to its potential as a drug target and biomarker, ADM also has potential as a therapeutic agent. The ADM peptide has been shown to have a variety of therapeutic properties, including its ability to stimulate the production of adrenocorticotropic hormone (ACTH) in the pituitary gland, which can help to regulate the production of hormones in the body.

ADM has also been shown to have a variety of effects on the regulation of inflammation and stress responses. This suggests that ADM may have potential as a therapeutic agent for the treatment of a variety of inflammatory and stress-related conditions.

Overall, ADM (proadrenomedullin N-20 terminal peptide) is a promising candidate for a variety of therapeutic and diagnostic applications. Further research is needed to fully understand the potential of ADM as a drug target and biomarker, and to determine its effectiveness in the treatment of a variety of diseases.

Protein Name: Adrenomedullin

Functions: AM and PAMP are potent hypotensive and vasodilatator agents. Numerous actions have been reported most related to the physiologic control of fluid and electrolyte homeostasis. In the kidney, am is diuretic and natriuretic, and both am and pamp inhibit aldosterone secretion by direct adrenal actions. In pituitary gland, both peptides at physiologically relevant doses inhibit basal ACTH secretion. Both peptides appear to act in brain and pituitary gland to facilitate the loss of plasma volume, actions which complement their hypotensive effects in blood vessels

The "ADM Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADM comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets